Back to results
US 2023/0414722 A1Published application
Injectable presentations, syringes and compositions with sustained and/or controlled release of lanreotide
AssigneeEdix SA
InventorsMaria Isabel GONZALEZ GARCIA, José Maria ROCA TORRELLAS, Tabatha BOURGOIS, Laurence LACHAMP, Frederic LACOMBE
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel injectable presentations, kits or syringes comprising a composition with sustained or controlled release of lanreotide or one of the salts thereof. The compositions of lanreotide or one of the salts thereof are packaged in a syringe having a diameter greater than 3.00 mm and provided with a needle having an outer diameter no greater than 1.00 mm.
Claims16
A pre-filled syringe wherein:
- a) said syringe is equipped with a needle having an outer diameter equal to or less than 1.00 mm and an inner diameter equal to or less than 0.80 mm and a length between 10 and 40 mm,
- b) said syringe contains a pharmaceutical composition comprising:
- 1) an aqueous solvent consisting of water
- 2) lanreotide or one of its salts, at a concentration ranging from 11 to 25% by weight of lanreotide relative to the total weight of the composition,
- 3) optionally a monomeric excipient accepted by the pharmacopoeia.
2 more elements
A pre-filled syringe wherein:
- c) said syringe is equipped with a needle having an outer diameter equal to or less than 1.00 mm and an inner diameter equal to or less than 0.80 mm and a length between 10 and 40 mm,
- d) said syringe contains a pharmaceutical composition comprising:
- 1) an aqueous solvent consisting of water and optionally of an organic solvent miscible with water,
- 2) lanreotide or one of its salts, at a concentration ranging from 11 to 25% by weight of lanreotide relative to the total weight of the composition,
- 3) optionally one or more amino acids,
- 4) optionally a monomeric excipient accepted by the pharmacopoeia.
3 more elements
Dependencies are inferred from the claim text.